Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma by Liao, Y H et al.
Upregulated ankyrin repeat-rich membrane spanning protein
contributes to tumour progression in cutaneous melanoma
YH Liao*,1, SM Hsu
2,3, HL Yang
1, MS Tsai
3 and PH Huang*,2,3
1Department of Dermatology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road, Taipei 100,
Taiwan;
2Department of Pathology, National Taiwan University Hospital, College of Medicine, National Taiwan University, No. 7, Chung-Shan South Road,
Taipei 100, Taiwan;
3Graduate Institute of Pathology, College of Medicine, National Taiwan University, No. 1, Sec. 1, Ren-Ai Road, Taipei 100, Taiwan
BACKGROUND: We have previously demonstrated that overexpression of ankyrin repeat-rich membrane spanning (ARMS) protein facilitates
melanoma formation via conferring apoptotic resistance. This study aims to investigate whether ARMS contributes to melanoma progression.
METHOD: Using immunohistochemistry, we graded the expression level of ARMS in 54 cases of primary melanoma and 46 cases of
metastatic melanoma. The immunointensity of ARMS was statistically correlated with individual clinicopathological characteristics.
By RNA interference, stable melanoma cell clones with ARMS-knockdown were constructed, and were used for in vitro scratch
wound, transwell invasion assays, and in vivo lung metastasis experiment.
RESULTS: Stronger immunointensity of ARMS was observed mostly in melanomas with Breslow tumour thickness 41.0mm (Fisher’s
exact test, P¼0.002) or with nodal metastasis (Fisher’s exact test, P¼0.026), and was correlated with a worse overall survival
in melanoma patients (log-rank test, P¼0.04). Depletion of ARMS inhibited migration, invasion, and metastatic potential of
melanoma cells in vitro and in vivo. Moreover, ARMS mediated melanoma cell migration and invasion through activation of the
extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signalling pathway.
CONCLUSION: Ankyrin repeat-rich membrane spanning expression, conjunctly with tumour thickness or ulceration, may serve as a
prognostic factor in patients with cutaneous melanoma.
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Cutaneous malignant melanoma is a highly aggressive cancer with
poor prognosis at advanced stage. It originates from malignant
transformation of melanocytes or nevocytes. During tumour
progression from radial growth phase to invasive vertical growth
phase, melanoma cells acquire metastatic capability and are
usually resistant to current chemotherapy (Miller and Mihm,
2006). Several histological factors have been shown to correlate
with the survival of melanoma patients, among which Breslow
tumour thickness is recognised as the most important prognostic
parameter (Sober et al, 1979). Although patients with thin
melanomas have an excellent prognosis following curative surgery,
those patients with increased thickness of the lesions (41.0mm
Breslow tumour thickness) are at risk for distant metastasis and
poor survival (Balch et al, 2001, 2009).
Reflecting its ontogenic origin as neural crest cells, mela-
noma frequently re-expresses molecules functioning in neuronal
development. For example, muscarinic acetylcholine receptors,
neuron-specific enolase, and microtubule-associated protein 2
are overexpressed in malignant melanomas (Dhillon and Rode,
1982; Lammerding-Koppel et al, 1997; Soltani et al, 2005). We
have demonstrated that ARMS (ankyrin repeat-rich membrane
spanning), a neuron-enriched transmembrane molecule inter-
acting with Trk, p75
NTR, Eph, and protein kinase D (Iglesias et al,
2000; Kong et al, 2001; Chang et al, 2004), is overexpressed in
cutaneous melanoma, while normal melanocytes and benign nevi
reveal negative or weak expression of ARMS (Liao et al, 2007).
Expression of ARMS in melanoma cells can confer resistance to
UVB-induced apoptosis through activating the MEK/extracellular
signal-regulated kinase (ERK) signalling pathway and thus
facilitates neoplastic transformation (Liao et al, 2007). In this
study, we investigated the role of ARMS in the malignant
progression of cutaneous melanoma. We analysed and statistically
correlated the immunointensity of ARMS in archived tissues with
the clinicopathological characteristics of patients with cutaneous
melanoma. Besides, statistical analysis was performed to correlate
the expression level of ARMS with the patient overall survival.
We further used RNA interference (RNAi) to knock down the
expression of ARMS in mouse and human melanoma cell lines,
and explored whether ARMS regulated the migratory/invasive
ability of melanoma cells via in vitro and in vivo assays.
MATERIALS AND METHODS
Antibodies
Polyclonal anti-ARMS antibody was generated as described
(Liao et al, 2007).
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A total of 100 melanoma lesions were selected by searching the
pathological records from 1997 to 2006 registered in National
Taiwan University Hospital (NTUH). Tissue blocks were derived
from the archives of Department of Pathology, NTUH, following
the guidelines set forth by Tissue Committee at NTUH. Selected
demographic information, including patient age, gender, tumour
location, tumour subtype, and outcome of survival was retrieved
from the hospital cancer registry.
Tissue microarray and immunohistochemistry
Tissue microarrays were constructed from archival formalin-fixed,
paraffin-embedded surgical specimens registered at Department of
Pathology, NTUH. Sampling of tumour regions was based on
visual alignment with the corresponding haematoxylin–eosin-
stained sections. Tissue cores were placed into a recipient paraffin
block with a tissue microarrayer (Manual Tissue Arrayer 1;
Beecher Instruments, Inc., Sun Prairie, WI, USA), and 5-mm
sections of the resulting microarray block were used for
immunohistochemistry. Immunohistochemistry for ARMS stain-
ing was performed as previously described (Liao et al, 2007). The
sections were examined, and the staining intensity of ARMS was
scored by two pathologists.
Cell culture, RNAi, and selection of stable-transfected
clones
Mouse B16-F0, -F1, -F10 and human A2058, A375 melanoma cell
lines were from the American Type Tissue Culture Collection
(ATCC; Manassas, VA, USA) and maintained in DMEM supple-
mented with 10% FBS, 4mML -glutamine, 100mgml
–1streptomycin,
and 100Uml
–1penicillin. The siRNA expression vector pSUPER.-
neoþGFP (OligoEngine, Seattle, WA, USA) was used for
expression of ARMS siRNA or control scrambled siRNA in B16-
F10 cells. The specific sequence for paired RNA oligonucleotides
contained nucleotides 4271–4289 for ARMS–RNAi-1 and 4840–
4858 for ARMS–siRNA-2 in mouse ARMS (accession number:
AK122478). Transfection and selection of ARMS knockdown stable
cell clones were performed as previously described (Liao et al,
2007). The RNAi rescue experiment was performed by transfecting
the ARMS–RNAi-2/B16-F10 stable clone with the ARMS–
pcDNA3.1C-Myc 4849T-C expression mutant as previously
described (Liao et al, 2007). Lentivirus carrying ARMS-specific
and scrambled small interfering RNA were purchased from the
National RNAi Core Facility of Academia Sinica (Taipei, Taiwan).
The sequences used for ARMS targeting was 50-GCACTGATTG
TGGCAGTGAAA-30. To generate recombinant lentivirus, 293FT
cells were co-transfected with the package, envelop, and siRNA-
expressing constructs. The virus-containing supernatant was
harvested and then used to infect A2058 and A375 human
melanoma cells. The infected cells were selected with puromycin
2mgml
–1 and the stable clones with the highest knockdown
efficiency were used for subsequent experiments.
Invasion assays
The invasiveness of melanoma cells were assayed using Boyden
chambers containing polycarbonate filters (Transwell 24, 8-mm
pore; Costar, Cambridge, MA, USA). Filters were coated with
2mgml
–1 Matrigel (Becton Dickinson, Heidelberg, Germany) at
371C overnight. Cells were harvested, resuspended in medium, and
placed in the upper wells at a density of 5 10
4 in 100ml DMEM. In
some cases, 10mM PD98059 (Calbiochem, La Jolla, CA, USA) or
dimethyl sulfoxide (DMSO; 0.02%) was added to the upper and
lower chambers. After incubation for 48h at 371C, membrane
toward upper chamber is scraped by cotton swabs. The cells
adhering to the lower surface were pre-fixed with 4% paraformal-
dehyde, stained with crystal violet, and counted by microscope
observation. For each membrane, the mean number of cells of five
randomly selected fields (100 ) in the centre of the filter was
obtained. The experiments were performed in triplicate.
Scratch wound assay
Melanoma cells were seeded in high density (5 10
5) into 35mm
dishes. Scratch wounds were made by creating three linear
denuded regions using a pipette tip per dish. The cells were
washed twice with medium before their incubation. In some cases,
10mM PD98059 or DMSO 0.02% was added in the medium. Six
fields per dish were photographed at 0 and 17h. Migration into the
wounds was documented and measured by MetaMorph7.6 Soft-
ware (Molecular Devises Inc., Sunnyvale, CA, USA). Each analysis
was performed in triplicate.
In vivo metastasis assay
Control and ARMS–RNAi stable B16-F10 cell lines were indivi-
dually injected into C57BL/6J mice via the lateral tail vein (5 10
5
cells per mouse, n¼5 in each group). Mice were killed 10 days
after intravenous injection. The lungs were fixed, photographed,
and the number of visible black nodules on the lung surface was
counted with a dissecting microscope. The lung tissue was then
embedded in paraffin and sectioned at three different levels; the
sections were stained with haematoxylin and eosin for light
microscopy.
Statistical analysis
The correlation between the intensity of ARMS expression and the
clinicopathological parameters was evaluated by two-sided Fisher’s
exact test. The impact of immunointensity of ARMS, tumour
thickness, ulceration, tumour location, age, and sex on patient
overall survival was assessed by the Kaplan–Meier method, and
differences between groups were analysed by the log-rank test.
Multivariate Cox proportional hazard regression analysis was used
to assess independent variables. Po0.05 were considered statisti-
cally significant. Statistics were performed with the SPSS 12.0
software (SPSS Inc., Chicago, IL, USA) and calculations on patient
survival were performed using the GraphPad Prism software
(GraphPad Software Inc., San Diego, CA, USA).
RESULTS
Overexpression of ARMS in primary and metastatic
melanoma with enhanced immunoreactivity at tumour
invasive fronts
We examined ARMS expression in tumours of different tissue type
by immunohistochemistry on tumour tissue arrays. In this
screening, ARMS was specifically expressed in tumours of
neuroepithelium origin, which included pheochromocytoma,
paraganglioma, central neurocytoma, and malignant melanoma
(Supplementary Figure S1A). Other epithelial-derived tumours had
barely or none detectable ARMS, which included 13 breast cancers
(6 ductal, 2 lobular, 3 medullary, 1 papillary, and 1 metaplastic
carcinoma), 12 lung cancers (5 squamous cell carcinoma and
7 adenocarcinoma), 6 gastric adenocarcinoma, 7 colon adenocar-
cinoma, 5 pancreatic adenocarcinoma, and 5 hepatocellular
carcinoma (Supplementary Figures S1B–F). For skin cancers,
expression of ARMS was specific to malignant melanoma in that
non-melanocytic skin cancers such as basal cell carcinoma (n¼5),
squamous cell carcinoma (n¼5), and extramammary Paget’s
disease (n¼3) did not express ARMS (Supplementary
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expressed in tumours of neuroectodermal origin.
On the basis of the results from the immunohistochemistry
screening of ARMS in tumour tissue arrays, we collected 100 cases
of primary cutaneous melanoma and metastatic melanoma for
further study. In accordance with our previous report (Liao et al,
2007), positive immunoexpression of ARMS was detected in 94.4%
of cases with primary malignant melanoma as well as in 87% of
cases with metastatic melanomas (Table 1). For primary melano-
ma, those ARMS-negative cases were all in situ lesions (Figure 1A).
When the immunointensity of ARMS was further graded into
weak, moderate, and strong intensity, stronger immunoreactivity
of ARMS was found at the invasive front of tumour nests facing
toward the dermis (Figures 1B and C, arrowheads) and in tumour
cells invading the nerves (Figure 1D). These observations suggest
that ARMS might be involved in the processes mediating local
tumour invasiveness. However, when the immunointensity of
ARMS was compared between metastatic melanoma and primary
melanoma, no statistical significance was observed (Fisher’s exact
test, P¼0.58; Table 1). Immunohistochemistry of ARMS demon-
strated two staining patterns: cytoplasmic granular and membra-
nous distribution (Figures 1E and F). Both patterns were seen in
primary cutaneous and metastatic melanoma with a similar
percentage.
The immunointensity of ARMS correlates with tumour
thickness in cutaneous melanoma
The clinical outcome of patients with cutaneous melanoma is
influenced by several factors including age, gender, ulceration,
tumour subtype, and in particular, tumour thickness (Balch et al,
2001). To examine whether ARMS expression in cutaneous
melanoma was associated with any clinicopathological parameter,
Figure 1 Immunohistochemical analysis of ARMS in cutaneous melanoma. Representative immunohistochemistry of ARMS in melanoma in situ
and melanoma at vertical growth phase. Ankyrin repeat-rich membrane spanning staining was negative in melanoma in situ ( 200, A). Stronger
immunointensity of ARMS was shown at the invasive front ( 200, B and C, arrow heads) and in tumour cells invading the nerve in the dermis at
vertical growth phase ( 100, D). Either cytoplasmic granular ( 400, E) or membranous ( 400, F) distribution pattern of ARMS was observed in
cutaneous melanoma.
Table 1 ARMS expression in primary cutaneous melanoma and
metastatic melanoma (n¼100)
ARMS immunostain intensity
Lesion n Negative Weak Moderate Strong P-value
a
Primary
melanoma
54 3 (5.6%) 20 (37.0%) 21 (38.9%) 10 (18.5%)
Metastatic
melanoma
46 6 (13.0%) 17 (37.0%) 14 (30.4%) 9 (19.6%) 0.58
Abbreviation: ARMS¼ankyrin repeat-rich membrane spanning.
aw
2-test.
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intensity of ARMS among the 54 patients with primary cutaneous
melanoma (Table 2). In this study group, 42 cases (77.8%) were
diagnosed as acral lentiginous melanoma, 5 cases (9.3%) as
nodular melanoma, and 7 cases as superficial spreading mela-
noma (13%). There were 26 men and 28 women included in
this study group, and their age ranged from 28 to 88 years
old (the median, 64 years). We used Breslow tumour thickness to
evaluate local invasion of melanoma. By this way, 15 cases (27.8%)
were classified as the subgroup with lesion p1.0mm, and the
remaining 39 cases (72.2%) were within the subgroup with lesion
41.0mm.
Analysis of ARMS expression and the clinical parameters
including age, gender, ulceration, and tumour subtypes did not
reveal any significant association (Table 2). However, when the
immunointensity of ARMS was compared in terms of Breslow
thickness, melanomas with tumour thickness 41.0mm tended to
have stronger ARMS immunoreactivity than lesions of melanoma
in situ. Positive ARMS staining was detected in all cases of
melanoma with thickness 41.0mm, of which 23.1% were strongly
stained. Whereas for thin melanomas (thickness o1.0mm), 20%
was nonreactive to ARMS, 80% showed weak-to-moderate ARMS
immunointensity, and none of them showed strong immunor-
eactivity toward ARMS (Fisher’s exact test, P¼0.002; Table 2).
When the immunointensity of ARMS was compared between
tumours with and without nodal/distant metastasis, 23.3% of
tumours with nodal metastasis showed strong ARMS expression,
compared with 8.3% of those without nodal metastasis (Fisher’s
exact test, P¼0.026; Table 2). Combined all together, it suggests
that ARMS expression is strongly upregulated in the cutaneous
melanomas with tumour thickness 41.0mm, and overexpression
of ARMS may be related to local dermal invasion and distant nodal
metastasis.
Prognostic relevance of ARMS expression
To evaluate whether the expression of ARMS in primary cutaneous
melanomas was related to patient outcome, a Kaplan–Meier
survival curve was constructed. The influence of tumour thickness
and ulceration, two well-recognised prognostic factors on overall
survival for cutaneous melanoma (Balch et al, 2009), was also
assessed in this study group as a method standard and a
comparison. Our analysis showed that both Breslow thickness
(log-rank test, P¼0.001) and tumour ulceration (log-rank test,
P¼0.007) were significant prognostic factors in our patients with
primary cutaneous melanoma. Importantly, a significant correla-
tion between the immunointensity of ARMS and the patient overall
survival was shown (log-rank test, P¼0.04; Figure 2). Shorter
median survival time in melanoma patients with stronger ARMS
expression (30 months) was revealed in comparison with the
patients with weak-to-moderate ARMS immunointensity
(42 months). Therefore, the expression level of ARMS may serve
as a molecular predictor for the prognosis of patients with primary
cutaneous melanoma.
To investigate whether the immunointensity of ARMS was an
independent prognostic marker for melanoma, we applied a
multivariate Cox’s proportional hazards model for the assessment
of the overall survival. The variables taken into consideration
included age, sex, tumour thickness, ulceration, tumour location,
and intensity of ARMS staining. Such analysis demonstrated that
only tumour thickness retained its significant predictive value for
the overall survival (P¼0.03, Supplementary Table 1). While
comparing patients with strong immunointensity to those with
negative, weak, or moderate ARMS staining, the hazard ratio was
1.28 (95% confidence interval 0.446–3.69, P¼0.64) without
reaching statistical significance (Supplementary Table 1).
ARMS-knockdown diminishes migratory and invasive
abilities of melanoma cells in vitro and in vivo through
downregulation of MEK/ERK activity
To investigate the role of ARMS in tumour invasion and migration,
we first examined the expression of ARMS in a panel of B16
melanoma cell lines with differential migratory ability. Western
blot analysis revealed a trend of progressively increased ARMS
expression associated with enhanced cell migratory ability. As
shown in Figure 3A, ARMS protein was expressed at low levels in
the benign mouse melanocyte cell line Melan-A (set as 1 for
comparison), and was moderately increased in the less metastatic
Table 2 Statistical correlations between the immunointensity of ARMS
and each clinicopathological characteristic in 54 patients with primary
cutaneous melanoma
Intensity of ARMS staining
Negative Weak Moderate Strong Total P-value
a
Age
p64 2 (7.4%) 11 (40.8%) 10 (37.0%) 4 (14.8%) 27 0.86
464 1 (3.7%) 9 (33.3%) 12 (44.4%) 5 (18.5%) 27
Sex
Male 2 (7.7%) 10 (38.5%) 8 (30.8%) 6 (23.1%) 26 0.098
Female 1 (3.6%) 10 (35.7%) 14 (50%) 3 (10.7%) 28
Tumour thickness (mm)
p1.0 3 (20.0%) 2 (13.3%) 10 (66.7%) 0 (0%) 15 0.002
b
41.0 0 (0.0%) 18 (46.1%) 12 (30.8%) 9 (23.1%) 39
Ulceration
Absent 3 (7.7%) 16 (41.0%) 17 (43.6%) 3 (7.7%) 39 0.053
Present 0 (0.0%) 4 (26.7%) 5 (33.3%) 6 (40.0%) 15
Lymph node invasion or distant metastasis
Negative 3 (12.5%) 6 (25.0%) 13 (54.2%) 2 (8.3%) 24 0.026
b
Positive 0 (0.0%) 14 (46.7%) 9 (30.0%) 7 (23.3%) 29
Tumour subtype
ALM 3 (7.1%) 15 (35.7%) 18 (42.9%) 6 (14.3%) 42 0.44
NM 0 (0.0%) 3 (60.0%) 0 (0%) 2 (40.0%) 5
SSM 0 (0.0%) 2 (28.6%) 4 (57.1%) 1 (14.3%) 7
Abbreviations: ALM¼acral lentiginous melanoma: ARMS¼ankyrin repeat-rich
membrane spanning; NM¼nodular melanoma; SSM¼superficial spreading
melanoma.
aFisher’s exact test;
bPo0.05.
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Figure 2 Kaplan–Meier survival analysis between ARMS expression and
the overall survival in melanoma patients. Patients with negative-, weak-, or
moderate-ARMS expression have a significantly better overall survival than
those with strong-ARMS expression (Po0.05, log-rank test).
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Figure 3 Depletion of ARMS deteriorates migratory and invasive abilities in melanoma cells via MEK/ERK signalling. (A) Western blot and quantification of
ARMS protein levels in mouse melanoma B16-F0, -F1, and -F10 cell lines as normalised to a-tubulin using densiometry showed increased expression of ARMS in
B16-F10 cells, the most aggressive melanoma cell line among them. Melan-A cells were given a value of 1 for comparison. Mouse brain lysate was used as a
positive control. (B) Western blotting showed effective ARMS knockdown by siRNA in human A2058 and A375 melanoma cells. (C) Effective RNAi of
endogenous ARMS in two independent mouse B16-F10 ARMS–RNAi stable cell clones as compared with their controls (scrambled). Levels of a-tubulin were
shown as a loading control. (D and E) ARMS knockdown in human A2058 and A375 melanoma cells resulted in a reduction of migration velocity (bar graph,
means±s.d.) in a wound-scratch assay (D) and decreased the invasive ability of the cells in a Boyden chamber invasion assay (E). Representative
photomicrographs with the cresyl violet stain and bar graph (means±s.d.) demonstrated the status of cellular invasion between the control and ARMS–RNAi
cells in a Boyden chamber invasion assay (magnification  200). The experiments were performed in triplicate. **Po0.01, Student’s t-test. (F and G) ARMS
silencing leaded to a significant reduction of migratory and invasive ability of B16-F10 cells via MEK/ERK signalling. Forced expression of RNAi-resistant ARMS
or constitutively active MEK-1 (CA-MEK1) into B16-F10 melanoma cells with ARMS-knockdown resulted in a significant increase in cellular migratory ability
(F, representative images and bar graph) and invasive potential in a Boyden chamber invasion assay (G, representative images and bar graph). Inhibition of
MEK/ERK by PD98059 treatment in control and ARMS–RNAi cells compromised cell migration (F, bar graph) and invasion (G, images and bar graph).
*Po0.05; **Po0.01; Student’s t-test. (H) Overexpression of RNAi-resistant ARMS or CA-MEK1 in ARMS–RNAi cells resulted in ERK1/2 phosphorylation
in melanoma cells compared with ARMS–RNAi cells. (I) The number of lung metastatic melanoma nodules was significantly decreased in mice receiving
intravenous injection of ARMS–RNAi melanoma cells compared with that of control mice. Tumour nodules were shown in representative grossly dissected
lungs (upper panels) and mouse lung tissue sections stained with haematoxylin and eosin (lower panels,  200) in each group. **Po0.01, Student’s t-test.
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respectively). By contrast, in highly metastatic B16-F10 melanoma
cells, high levels of ARMS expression were observed (10.3-fold
increase). When immunofluorescence was performed in human
melanoma cell lines, colocalisation of ARMS with actin and relative
enhancement of ARMS in invading filopodia or lamellipodia were
observed (Supplementary Figure S2). Taken together, these results
suggest that ARMS may be involved in melanoma progression by
regulating cell migration and invasion.
To explore the cause–effect relationship between ARMS
expression and melanoma aggressiveness, we used RNAi to
knockdown ARMS expression in three metastatic melanoma cell
lines with abundant ARMS expression (human A2058, human
A375, and mouse B16-F10 cells). Expression of ARMS in human
A2058 and A375 cells was silenced to the level around 20 and 40%,
respectively, of that in control scrambled cells (Figure 3B). For
mouse B16-F10 melanoma cells, two independent clones targeted
by different nucleotide sequences (designated as ARMS–RNAi-1
and ARMS–RNAi-2) had ARMS expression to the level around
40 and 20% of that in control, respectively (Figure 3C). The
proliferation rate of these constructed stable clones was not
affected by ARMS silencing, as evidenced by Trypan blue exclusive
assay (data not shown).
The migratory and invasive capacities of melanoma cells with or
without ARMS–RNAi were assessed by in vitro wound scratch and
chamber invasion assays. As shown in Figure 3D, ARMS silencing
decreased migratory velocity in both A2058 and A375 cells. The
mean migratory velocity in A2058 cells was 8.3±2.0mmh
–1 for
ARMS–RNAi vs 14.0±2.1mmh
–1 for control cells, and in A375
cells was 8.2±1.6mmh
–1for ARMS–RNAi vs 11.1±1.4mmh
–1for
control cells (Student’s t-test, Po0.01). Knockdown of ARMS also
decreased invasion capacity of A2058 (mean±s.d.; 154.0±31.4
cells per 100  field in control cells vs 25.3±4.7 cells in ARMS–
RNAi cells) and A375 cells (380.7±68.5 cells in control cells vs
76.2±12.5 cells in ARMS–RNAi cells) as evidenced by Boyden
chamber invasion assay (Figure 3E; Student’s t-test, Po0.01).
Similarly, ARMS silencing in mouse B16-F10 melanoma cells
significantly demised the migration potential of tumour cells in
wound scratch assay (17.8±3.1mmh
–1 for ARMS–RNAi vs
26.5±2.9mmh
–1 for control) and led to a significant decrease in
their invasive capability (169±17.6 cells per 100  field in control
cells vs 35±4.4 cells in ARMS–RNAi cells; Figure 3F; Student’s
t-test, Po0.01). Reintroduction of RNAi-resistant full-length
ARMS into ARMS-knockdown cells significantly recovered the
compromised migratory and invasive capability of melanoma cells
resulting from ARMS depletion as evident by wound scratch
(21.6±2.0mmh
–1, 43.5% recovery compared with ARMS–RNAi
cells; Figure 3F) and by the chamber invasion assay (99.7±10.5
cells per 100  field, 49.3% recovery compared with ARMS–RNAi
cells; Figure 3G). These results suggest that knockdown of ARMS
significantly decreases the migratory and invasive potential of
human A2058, A375, and murine B16-F10 melanoma cells.
Given that MEK/ERK molecules are downstream effectors of
ARMS, we thus examined the role of MEK/ERK signalling in
ARMS-mediated migration and invasion. First, we introduced
constitutively active MEK1 (CA-MEK1) into ARMS-knockdown
cells and observed that the compromised migratory and invasive
capability of melanoma cells resulting from ARMS depletion was
recovered (Figures 3F and G). Second, treatment of B16-F10
control cells with a MEK-specific inhibitor PD98059 resulted in a
significant decrease in migratory and invasive ability similar to that
in ARMS–RNAi cells (Figures 3F and G). Third, treatment of
ARMS–RNAi cells with PD98059 further inhibited cell migration
and invasion in comparison with vehicle-treated ARMS–RNAi
cells (Figures 3F and G). Western blotting confirmed that both
phospho-ERK1/2 were markedly upregulated by expression of
CA-MEK1 and RNAi-resistant ARMS in the ARMS–RNAi cells that
had decreased phosphorylated ERKs, while the expression levels of
total ERK proteins were not altered (Figure 3H). Collectively, these
results suggest that MEK/ERK signalling, which is downstream of
ARMS regulates the migratory and invasive abilities in melanoma cells.
We then examined whether ARMS depletion interfered with the
metastatic behaviour via murine lung metastasis assay. In all,
5 10
5 control or ARMS–RNAi B16-F10 cells were injected into
C57BL/6J mice via the tail veins, and the animals were assessed for
lung metastases 10 days after injection (n¼5 in each group). As
revealed in Figure 3I, an average of 170±38.8 lung tumours
developed in mice injected with control scrambled cells. By
contrast, only 12±3.5 lung tumours were seen in mice injected
with ARMS–RNAi melanoma cells (Student’s t-test, Po0.01).
Combined all together, the in vitro and in vivo data suggest that
ARMS silencing deters melanoma cells from invasion and distant
metastasis through downregulation of MEK/ERK signalling activity.
DISCUSSION
In this study, we demonstrate that ARMS is overexpressed in
primary melanoma and in metastatic melanoma as well. The
immunointensity of ARMS tends to be stronger in melanoma with
tumour depth 41.0mm, and is intensively localised at the invasive
front of melanoma nests in the dermis. Besides, stronger ARMS
expression is more frequently found in cases of cutaneous
melanoma with lymph node or distant metastasis. Kaplan–Meier
analysis further demonstrates that increased ARMS expression
correlates negatively with the overall survival of melanoma
patients. Therefore, ARMS may serve as a prognostic molecular
marker in association with tumour thickness in cutaneous
melanoma.
We further demonstrate that ARMS participates in the regula-
tion of migratory/invasive ability of melanoma cells by in vitro and
in vivo assays. We provide evidence that ARMS-mediated
migratory and invasive abilities depend on the activated
MEK/ERK signalling pathway, because constitutively active MEK
reverts the compromised migratory and invasive activities caused by
ARMS depletion and MEK1 inhibitor PD98059 leads to decreased
migratory and invasive potential in melanoma cells. Therefore,
activation of the ARMS/MEK/ERK signalling pathway is important
for the acquisition of an invasion and metastatic phenotype in
melanoma cells. As ARMS forms protein complex with Trk receptor
tyrosine kinases or p75 neurotrophin receptor, and can transduce
neurotrophin-mediated signalling that leads to ERK activation
(Kong et al, 2001; Chang et al, 2004; Arevalo et al, 2004, 2006), it is
interesting to identify that expression of neurotrophin, neurotro-
phin receptors, and phospho-ERK1/2 increases in a stage-specific
trend during melanoma progression, just as ARMS does as shown in
this study (Brocker et al, 1991; Easty et al, 1995; Walch et al, 1999;
Innominato et al, 2001; Shonukan et al, 2003; Smalley, 2003; Zhuang
et al, 2005). Similar to the distribution of ARMS at invading fronts
of melanoma nests in this study, expression of phospho-ERK and
p75NTR is more intense towards the deep tumour margins of thick
melanoma (Shonukan et al, 2003; Zhuang et al,2 0 0 5 ) .A l s oi n
accordance with the positive correlation between ARMS expression
and the overall survival in patients with cutaneous melanoma,
statistical analysis also shows a worse overall survival for phospho-
ERK expression in patients with melanoma over 1mm in thickness
(Zhuang et al, 2005).
It is presently unclear how ARMS regulates migration and invasion
in melanoma cells. The colocalisation of ARMS with F-actin on the
cell cortex and cell projections in melanoma cells suggests that actin
reorganisation could be modulated by ARMS to affect cell motility.
Noticeably, it has been reported that p75NTR, an interacting receptor
with ARMS, can mediate neurotrophin-dependent melanoma cell
migration through specifically interacting with actin-bundling protein
fascin (Shonukan et al, 2003). A recent study also reveals that ARMS
is concentrated on filopodia and lamellipodia in developing neurons
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We thus speculate that ARMS might have a role in the regulation
of cytoskeleton and hence affect cell motility in both physiological
and pathological processes, which definitely needs further experi-
ments to prove the hypothesis.
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